BEOVU: A NEW TREATMENT FOR WET MACULAR DEGENERATION

AT STRATHFIELD RETINA CLINIC, OUR TEN RETINAL SPECIALISTS HAVE LIMITED ACCESS TO A NEW INJECTION TYPE FOR THE TREATMENT OF WET MACULAR DEGENERATION.

Beovu (brolucizumab) is currently approved for limited use under an early access scheme, of which our ten retinal specialists are taking part in. While we do have access to this treatment, it is best that any new or existing patients discuss the new treatment with their specialist to see if they are suitable to switch over from their current injection to Beovu or to begin initial treatment with Beovu.

For existing patients, this can be discussed at the next scheduled injection visit and, if suitable, treatment with Beovu can be administered on the day.

For new patients, this treatment can be discussed at the initial consultation with their doctor.

For more information, please contact us at info@strathfieldretina.com.au or on (02) 9746 3378